Peter Ordentlich
Founder at SYNDAX PHARMACEUTICALS, INC.
Net worth: 5 451 $ as of 2024-04-29
Peter Ordentlich active positions
| Companies | Position | Start | End |
|---|---|---|---|
| SYNDAX PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2013-10-31 | - |
| Founder | 2005-10-10 | - |
Career history of Peter Ordentlich
Former positions of Peter Ordentlich
| Companies | Position | Start | End |
|---|---|---|---|
X-Ceptor Therapeutics, Inc.
 X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Corporate Officer/Principal | - | - |
| The Salk Institute for Biological Studies | Corporate Officer/Principal | - | - |
Training of Peter Ordentlich
| University of Pennsylvania | Doctorate Degree |
Statistics
International
| United States | 5 |
Operational
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
Sectoral
| Consumer Services | 3 |
| Health Technology | 2 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| SYNDAX PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
X-Ceptor Therapeutics, Inc.
X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Commercial Services |
- Stock Market
- Insiders
- Peter Ordentlich
- Experience